Inovio says FDA agrees with rolling BLA submission for rare disease asset

1 hour ago 1

The U.S. FDA is in agreement with Inovio Pharmaceuticals (NASDAQ:INO) regarding its rolling BLA submission plan for INO-3107 for Recurrent Respiratory Papillomatosis.
The pharma said it projects it will finish the submission in the next few months with an eye